loading
前日終値:
$18.39
開ける:
$18.29
24時間の取引高:
233.82K
Relative Volume:
0.89
時価総額:
$366.91M
収益:
$116.88M
当期純損益:
$-25.09M
株価収益率:
-127.71
EPS:
-0.14
ネットキャッシュフロー:
$-20.74M
1週間 パフォーマンス:
-11.49%
1か月 パフォーマンス:
-17.91%
6か月 パフォーマンス:
+8.89%
1年 パフォーマンス:
+20.81%
1日の値動き範囲:
Value
$17.75
$18.63
1週間の範囲:
Value
$17.75
$20.72
52週間の値動き範囲:
Value
$7.4843
$29.82

Rigel Pharmaceuticals Stock (RIGL) Company Profile

Name
名前
Rigel Pharmaceuticals
Name
セクター
Healthcare (1166)
Name
電話
650-624-1100
Name
住所
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Name
職員
0
Name
Twitter
@rigelpharma
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
RIGL's Discussions on Twitter

RIGL を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RIGL
Rigel Pharmaceuticals
17.88 366.91M 116.88M -25.09M -20.74M -0.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-04-03 再開されました Piper Sandler Neutral
2022-06-09 ダウングレード Citigroup Buy → Neutral
2022-06-08 ダウングレード Cantor Fitzgerald Overweight → Neutral
2022-06-08 ダウングレード Piper Sandler Overweight → Neutral
2022-03-23 開始されました B. Riley Securities Neutral
2020-11-09 ダウングレード JP Morgan Overweight → Neutral
2019-11-15 再開されました Cantor Fitzgerald Overweight
2019-09-26 再開されました JP Morgan Overweight
2019-03-01 繰り返されました Cantor Fitzgerald Overweight
2018-08-27 開始されました Citigroup Buy
2018-05-02 繰り返されました Cantor Fitzgerald Overweight
2017-12-21 再開されました Piper Jaffray Overweight
2017-12-15 開始されました Cantor Fitzgerald Overweight
2017-11-06 再開されました H.C. Wainwright Buy
2017-03-09 繰り返されました H.C. Wainwright Buy
2016-08-31 繰り返されました H.C. Wainwright Buy
2016-08-30 繰り返されました Piper Jaffray Overweight
2016-07-13 開始されました H.C. Wainwright Buy
2016-06-13 開始されました Piper Jaffray Overweight
2016-04-22 アップグレード JP Morgan Neutral → Overweight
2013-04-08 繰り返されました Stifel Buy
2012-11-29 開始されました UBS Neutral
2012-11-06 繰り返されました Oppenheimer Outperform
2012-03-26 開始されました Canaccord Genuity Hold
2010-12-10 ダウングレード MP Advisors Outperform → Market Perform
すべてを表示

Rigel Pharmaceuticals (RIGL) 最新ニュース

pulisher
Mar 27, 2025

Rigel settles patent litigation regarding its immune thrombocytopenia treatment - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel Pharma stock rises on patent settlement (RIGL:NASDAQ) - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel, Hetero Settle Patent Suit Over Platelet-Booster Tavalisse - Bloomberg Law

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel climbs on blood disorder drug patent settlement - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel settles patent litigation regarding its immune thrombocytopenia treatment (RIGL:NASDAQ) - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel Pharmaceuticals Settles Patent Litigation Over Tavalisse - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel Pharmaceuticals resolves patent litigation related to Tavalisse - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel Announces Settlement Agreement Resolving TAVALISSE® (Fostamatinib Disodium Hexahydrate) Patent Litigation - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel settles patent litigation over TAVALISSE treatment - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Rigel Wins Patent Battle: TAVALISSE Exclusivity Protected Until 2032 in Major Settlement - StockTitan

Mar 27, 2025
pulisher
Mar 25, 2025

(RIGL) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 25, 2025
pulisher
Mar 25, 2025

Bristol-Myers Squibb expands immuno-oncology pipeline with Flexus Biosciences, Rigel Pharmaceuticals deals - FirstWord Pharma

Mar 25, 2025
pulisher
Mar 21, 2025

Rigel Pharmaceuticals appoints Mark W. Frohlich to board of directors - MSN

Mar 21, 2025
pulisher
Mar 15, 2025

Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are - Yahoo Finance

Mar 15, 2025
pulisher
Mar 15, 2025

(RIGL) Investment Analysis and Advice - Stock Traders Daily

Mar 15, 2025
pulisher
Mar 13, 2025

Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 11, 2025

Rigel Looks Interesting, But Let's Wait For A Lower Price (NASDAQ:RIGL) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 10, 2025

Rigel Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel Pharmaceuticals adds oncology expert to board By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

SEC Form 4 filed by Director Frohlich Mark W - Quantisnow

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel Pharmaceuticals appoints new board member - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update - Quantisnow

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel Pharmaceuticals Appoints Dr. Frohlich to Board - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel appoints Mark W. Frohlich to its board -March 10, 2025 at 12:01 pm EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel Pharmaceuticals adds oncology expert to board - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors - StockTitan

Mar 10, 2025
pulisher
Mar 09, 2025

Rhumbline Advisers Has $423,000 Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

FY2025 EPS Estimates for RIGL Increased by Cantor Fitzgerald - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Citigroup Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Rigel Pharmaceuticals Implements 1-for-10 Reverse Stock Split: Balancing Nasdaq Compliance and Investor Appeal - MSN

Mar 08, 2025
pulisher
Mar 08, 2025

Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded by StockNews.com to “Buy” - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

What is B. Riley’s Forecast for RIGL Q1 Earnings? - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

What is HC Wainwright’s Estimate for RIGL Q1 Earnings? - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Earnings call transcript: Rigel Pharmaceuticals Q4 2024 sees strong growth By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance

Mar 07, 2025
pulisher
Mar 07, 2025

Rigel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

B. Riley Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

HC Wainwright Reiterates Buy Rating for Rigel Pharmaceuticals (NASDAQ:RIGL) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

What is B. Riley’s Estimate for RIGL FY2026 Earnings? - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Q3 Earnings Forecast for RIGL Issued By HC Wainwright - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Rigel Pharmaceuticals price target raised to $55 from $49 at Citi - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Citi lifts Rigel stock price target to $55, maintains Buy rating - Investing.com

Mar 06, 2025
pulisher
Mar 05, 2025

Rigel Pharmaceuticals Reports Record Sales and Strategic Growth - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 05, 2025
pulisher
Mar 05, 2025

Rigel Pharmaceuticals stock holds Buy rating, $57 target By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Rigel Pharmaceuticals stock holds Buy rating, $57 target - Investing.com India

Mar 05, 2025

Rigel Pharmaceuticals (RIGL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Rigel Pharmaceuticals (RIGL) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Schorno Dean L
EVP & Chief Financial Officer
Feb 05 '25
Sale
21.93
1,734
38,020
57,235
Santos David A
EVP, Chief Commercial Officer
Feb 04 '25
Sale
20.92
2,125
44,457
53,500
Santos David A
EVP, Chief Commercial Officer
Feb 05 '25
Sale
21.93
1,796
39,379
51,704
RODRIGUEZ RAUL R
CEO, President
Feb 04 '25
Sale
20.92
4,952
103,601
243,854
RODRIGUEZ RAUL R
CEO, President
Feb 05 '25
Sale
21.93
4,400
96,474
239,454
Furey Raymond J.
EVP, GC, CCO & Corp Sec
Feb 04 '25
Sale
20.92
1,448
30,294
40,169
Furey Raymond J.
EVP, GC, CCO & Corp Sec
Feb 05 '25
Sale
21.93
1,339
29,359
38,830
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):